

Asia Area Webinar Series (乳癌教育線上研討會)

- 計畫宗旨：藉由 Asia Area Webinar Series (乳癌教育線上研討會)這個線上平台，希望能提供台灣醫療相關人員一個乳癌新知識分享、學術互相交流的管道，Asia Area Webinar-乳癌教育線上研討會預計在 2025 年舉辦三場跨國線上研討會，邀請國內外乳癌專家們分享國際會議乳癌最新研究發表或臨床試驗結果，搭配台灣與亞洲各國臨床使用經驗分享，期待能提供醫療人員更多學習分享交流的管道，提升台灣乳癌治療水平、促進國內外醫療進步、提供醫師、醫療相關人員和病患三贏的分享平台。
- 預定日期：2025 年 1 月至 2025 年 12 月，舉辦三場線上亞洲區乳癌教育研討會議，邀請各醫院醫師分享學術新知與臨床經驗，並廣邀各醫療人員線上參與學習。
- 預定時間：19:00-20:40 (1 小時 40 分鐘)
- 議程表：
 - ✓ 第一場

Bridging Breast Cancer Expertise of Trop2 ADC in Clinical Practice: <u>2025/2/12 Wed.</u>			
Time	Topic	Speaker	Facilitator
19:00-19:10 (10 min)	Introduction	Prof. Yen-Shen Lu	
19:10-19:30 (20 min)	<ul style="list-style-type: none"> ❑ Evolving Role of ADCs in management of HER2- mBC ❑ Real world experiences of Trodelvy in HER2- mBC treatment: <ul style="list-style-type: none"> • Pre-treated mHR+HER2- 	Dr. Shaheenah Dawood	Prof. Yen-Shen Lu
19:30-20.00 (30 min)	<ul style="list-style-type: none"> ❑ Recent experiences with Trodelvy in HER2- mBC -Improving outcomes for patients with mTNBC -Expanding possibilities in HR+/HER2- mBC <ul style="list-style-type: none"> • Taiwan • Singapore • Hong Kong 	Dr. Ming-Shen Dai Dr. Samuel Ow Dr. Josephine Tsang	Prof. Yen-Shen Lu
20.00-20:30 (30 min)	Panel Discussion	Dr. Shaheenah Dawood Prof. Yen-Shen Lu Dr. Ming-Shen Dai Dr. Josephine Tsang	Dr. Samuel Ow
20:30-20:40 (10 min)	Closing	Dr. Josephine Tsang	

Organizer: Gilead Taiwan

Co-organizer: Taiwan medical society, Singapore Oncology Society (SSO), Hong Kong Medical Oncology Society

HCPs Only

Time: 2025/02/12 (Wed.) 19:00~20:40

Platform: Virtual meeting through Zoom

題目	演講者	內容大綱
Evolving Role of ADCs in management of HER2- mBC	Dr. Shaheenah Dawood	Sacituzumab Govitecan (SG)在 2024 年在台上市，Dr. Shaheenah Dawood 將帶我們複習 SG 在三陰性乳癌和賀爾蒙陽性 HER2 陰性轉移性乳癌的兩個樞紐試驗重要結果與次族群分析，另外也將分享針對亞洲族群 EVER132-002 的研究結果，再與我們分享他在歐洲的三陰性乳癌以及荷爾蒙受體陽性病人使用 Sacituzumab Govitecan 的治療經驗，探討其在臨床應用中的重要性。通過 Dr. Shaheenah Dawood 的分享，與會者可以深入了解 Sacituzumab Govitecan 的在臨床上的治療角色，有助於拓展對於這一治療方法的認識和理解。
Recent experiences with Trodelvy in HER2- mBC	Dr. Ming-Shen Dai	三總戴明燊醫師(Dr. Ming-Shen Dai)將與我們分享台灣使用 Sacituzumab Govitecan 在轉移性乳癌病人的使用經驗，探討其在臨床應用中的重要性。通過戴醫師的分享，讓台灣與亞洲與會者可以深入了解 Sacituzumab Govitecan 的在台灣臨床上的使用經驗以及副作用的處置，有助於拓展對於這一治療方法的認識和理解。
	Dr. Samuel Ow	Dr. Samuel Ow 將與我們分享新加坡使用 Sacituzumab Govitecan 在轉移性乳癌病人的使用經驗，讓亞洲與會者可以相互分享 Sacituzumab Govitecan 在亞洲族群臨床上的應用以及可能面對的安全性問題，有助於臨床醫療人員更熟悉轉移性乳癌的治療。
	Dr. Josephine Tsang	Dr. Josephine Tsang 將與我們分享香港使用 Sacituzumab Govitecan 在 HER2-轉移性乳癌病人的使用經驗，由於各國家治療現況有些不同，醫保制度也不盡相同，希望能讓亞洲與會者可以相互分享 Sacituzumab Govitecan 在亞洲族群的臨床經驗，以及其他臨床治療選擇如: T-DXd2. 其他化療等，加強各國臨床醫療人員在轉移性乳癌的治療交流。
Panel Discussion	All	針對以上四位醫師的分享，希望能針對新藥 Trop2 ADC 的療效與安全性有更進一步的認識，並相互討論在亞洲各國家間，臨床實務上在 SG 的使用經驗與如何妥善處置副作用。

1st Asia Area Trodelvy (sacituzumab govitecan) Webinar Series

- Time: 12 Feb-2025 7:00 pm ~ 8:40 pm Platform: Zoom
- Educational credits application (pending): Taiwan medical society credit, Singapore Oncology Society (SSO) CME: 1 point, Hong Kong Medical Oncology Society

Bridging Breast Cancer Expertise of Trop2 ADC in Clinical Practice

Time	Topic	Speaker	Facilitator
19:00~19:10 (10 min)	Introduction	 Prof. Yen-Shen Lu	
19:10~19:30 (20 min)	<input type="checkbox"/> Evolving Role of ADCs in management of HER2- mBC (5min) <input type="checkbox"/> Real world experiences of Trodelvy in HER2- mBC treatment: <ul style="list-style-type: none"> • Pre-treated mHR+HER2- (15min) 	Dr. Shaheenah Dawood	Prof. Yen-Shen Lu
19:30~20.00 (30 min)	<input type="checkbox"/> Recent experiences with Trodelvy in HER2- mBC -Improving outcomes for patients with mTNBC -Expanding possibilities in HR+/HER2- mBC <ul style="list-style-type: none"> • Taiwan (10min) • Singapore (10min) • Hong Kong (10min) 	 Dr. Ming-Shen Dai  Dr. Samuel Ow  Dr. Josephine Tsang	Prof. Yen-Shen Lu
20.00~20:30 (30 min)	Panel Discussion	Dr. Shaheenah Dawood Prof. Yen-Shen Lu Dr. Ming-Shen Dai Dr. Josephine Tsang	Dr. Samuel Ow
20:30~20:40 (10 min)	Closing	Dr. Josephine Tsang	

Dr. Yen-Shen Lu CV attached

Rationale of **chairperson & panelist**

a) Prof. Lu brings over two decades of experience as an Attending Doctor at the Department of Oncology, National Taiwan University Hospital, making him highly knowledgeable in clinical and academic field.

b) As an initiator, protocol writer, and principal investigator of multiple clinical trials, Prof. Lu's research acumen aligns well with our seminar's objective to showcase the latest advancements and clinical practices in oncology.

c) International Recognition and Contributions: Prof. Lu is a respected speaker at major conferences, such as the Asia Oncology Summit and Global Breast Cancer Conference, underscoring his ability to engage and convey insights to a global audience effectively.

d) With over 60 publications in top-tier journals, including Lancet Oncology and Cancer Research, Prof. Lu's scientific contributions highlight his depth of knowledge and commitment to advancing cancer research, making him an ideal choice to lead our discussions.



Dr. Shaheenah Dawood

CV attached



Shaheenah Dawood

Mediclinic City Hospital Dubai
United Arab Emirates

Rationale of **speaker and panelist**

Shaheenah Dawood is a consultant medical oncologist and professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple Scholar-in-Training Awards and ASCO Merit Awards. She has served as an editorial fellow at the New England Journal of Medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer-reviewed original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the Excellence in Oncology Care summit that is held annually in Dubai and is co-president of the Asia-Pacific Breast Cancer Summit (APBCS) and Asia-Pacific Gastroenterology Cancer Summit (APGCS). She has also recently launched the International BRCA Forum and Young Women's Forum.



Dr. Ming-Shen Dai CV attached

Rationale of **speaker and panelist**

a)Dr. Dai is an Attending Physician in the Division of Hematology and Oncology at Tri-Service General Hospital, bringing substantial clinical expertise to discuss real-world application of sacituzumab govitecan.

b)As an Associate Professor at National Defense Medical Center and a Chief of the Division of Oncology, Dr. Dai has demonstrated leadership in oncology, which aligns with the goal of presenting well-grounded insights on the efficacy of sacituzumab govitecan.

c)Dr. Dai has published extensively in peer-reviewed journals and received awards such as the Young Investigators' Award in Clinical Research, showcasing his credibility and the value of his insights for an international audience.

d)Dr. Dai's experience as a principal investigator and co-investigator in various clinical trials makes him well-suited to discuss clinical experiences and outcomes, contributing significantly to the seminar's objective of enhancing understanding of the impact of sacituzumab govitecan in Taiwan



Dr. Samuel Ow

Bio:

https://www.ncis.com.sg/For-Patients-and-Visitors/Pages/Find-a-Doctor-Details.aspx?docid=Samuel_Ow

Rationale of moderator, speaker & panelist

- a) Dr. Ow is a Senior Consultant Medical Oncologist in the Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS).
- b) His clinical and research interests are in Breast Cancer and Clinical Cancer Genetics. He received a Master of Public Health with concentration in Epidemiology and Biostatistics from the Johns Hopkins Bloomberg School of Public Health on an Academic Medicine Development Award.
- c) He is a co-investigator in several investigator-initiated and multi-national clinical trials and has published his research in peer-reviewed journals. He also sits on the committee for the Breast Cancer Awareness Campaign at the institutional and national level.
- d) His strong clinical profile in breast oncology and real-world use experience with sacituzumab govitecan for his Breast Cancer patients make him a great choice as a speaker and moderator at this meeting so that he can lead the discussions of the real-world case sharing and discussions



**Dr. Tsang Wing Yan,
Josephine
CV attached**

Rationale of **speaker and panelist**

a)Dr. Tsang has undergone extensive training, specializing in advanced internal medicine, dermatology, and medical oncology. She recently completed a Breast Preceptorship at the Bobst International Centre at MSKCC.

b)Currently, Dr. Tsang serves as a resident specialist in the Department of Medical Oncology at Queen Mary Hospital and as a Clinical Practitioner at the University of Hong Kong. With her extensive clinical experience in breast cancer, she is well-positioned to provide valuable insights on best practices for managing TNBC cases in Hong Kong to the regional audience.

c)In addition to her Breast Preceptorship at the Bobst International Centre, Dr. Tsang was awarded the prestigious Li Ka Shing Fellowship for Internal Medicine earlier this year in 2024.

d)Dr. Tsang has co-authored publications in peer-reviewed journals, and her real-world clinical experience further qualifies her as an ideal speaker for sharing cases with a broader audience across the region.

